Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Found 41305 matches for

Vaccitech, an Oxford University spinout company developing a universal flu vaccine has secured £20 million in Series A financing.

Search results

Found 41305 matches for

Physiology, cellular & molecular biology

Cancer biology

Tropical medicine & global health

Genomic medicine

Protein science & structural biology

Immunology & infectious disease

Similar stories

Nigeria rolls out new Oxford R21 malaria vaccine

Developing the first cancer prevention vaccine for Lynch syndrome

PSI collaborates with Oxford's History of Science Museum on new exhibition

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Caesar Atuire appointed International Association of Bioethics President

Bangladesh Health Minister visits the Centre for Medicines Discovery